Method for small molecule acid assisted liquid phase ultrasonic exfoliation of natural mineral drugs
By using a small molecule acid-assisted liquid-phase ultrasonic exfoliation method, combined with ultrasonic cavitation and coordination, the problem of fine processing of natural mineral drugs has been solved, realizing the preparation of efficient, green, and morphology-controllable nanosheets or nanoplates, improving processing efficiency and the biosafety of the products.
Patent Information
- Application Number
- CN202610394774.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-28
- Publication Date
- 2026-06-30
Smart Images

Figure CN122301574A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of fine processing and modification technology of mineral materials, specifically relating to a method for small molecule acid-assisted liquid-phase ultrasonic exfoliation of natural mineral drugs. Background Technology
[0002] Liquid-phase exfoliation (LPE) is a key technology that disperses layered or bulk materials into atomic or nanoscale flakes / particles by weakening the interlayer or interparticle interactions. Since its successful application in the preparation of two-dimensional materials such as graphene and molybdenum disulfide (MoS2), LPE has become an ideal choice for balancing material performance and industrial production requirements due to its advantages such as mild processing conditions (no high-temperature or high-pressure environment required), maximum preservation of the intrinsic structure and active components of the material, and good scalability potential. In traditional Chinese medicine, natural mineral drugs (such as gypsum, talc, realgar, and orpiment) play an important role, and their efficacy largely depends on the dissolution efficiency and bioavailability of the active ingredients. However, traditional processing methods (such as mechanical grinding, water levigation, and calcination) have significant limitations: mechanical grinding often leads to uneven particle size distribution, and some active ingredients are trapped inside the crystal lattice and difficult to release; while water levigation can improve particle fineness, it suffers from low yield and long processing time, and it is also difficult to achieve efficient separation of harmful impurities (such as free arsenic in realgar) from active ingredients; calcination may destroy heat-sensitive active components and even induce phase transformation, leading to the formation of toxic byproducts. Therefore, developing a new technology that can achieve refined and efficient processing of mineral drugs is particularly urgent. Liquid phase exfoliation, with its low-destructiveness to material structure and precise control over particle size, provides a potential new approach for the modern processing of natural mineral drugs.
[0003] Currently, the development of liquid-phase exfoliation technology has formed a multi-dimensional optimization system, laying the foundation for its application in the processing of natural mineral drugs. Regarding solvent systems, a variety of options have been developed, including organic solvents (such as N-methylpyrrolidone and dimethylformamide), water-based solvents (such as pure water and water-surfactant systems), and mixed solvents (such as ethanol / water and dimethylformamide / water), which can be rationally selected based on the hydrophilicity / hydrophobicity and component stability of the mineral drug. In terms of external force-assisted technologies, liquid-phase ultrasonic exfoliation has become the mainstream method for balancing exfoliation efficiency and product quality due to its simple operation and controllable shear force. This technology effectively disrupts the interaction forces between mineral drug particles through cavitation effects and gentle shearing, while avoiding component structural damage that may be caused by traditional mechanical pulverization. Regarding additive-assisted strategies, surfactants (such as hexadecyltrimethylammonium bromide) and small molecule organic compounds (such as pyrene derivatives) have been widely used to improve the dispersion stability of exfoliated products. However, existing additive systems still lack specificity for the multiple requirements in the processing of natural mineral drugs, such as the retention of active ingredients, the removal of harmful impurities, and biocompatibility. It is worth noting that small molecule acid compounds (such as hydroxybenzoic acid) not only have intercalation and exfoliation capabilities, but can also promote the dissolution and separation of some harmful impurities (such as metal ions) in mineral drugs through acid hydrolysis, providing a new research direction for the development of liquid phase exfoliation systems for mineral drugs.
[0004] Current technologies for processing natural mineral drugs and applying liquid-phase exfoliation still face a series of key bottlenecks, severely restricting the further expansion and industrialization of liquid-phase ultrasonic exfoliation technology in this field. From the perspective of the nature of processing technology, traditional natural mineral drug processing methods have long struggled to achieve an effective balance between refined processing and retention of active ingredients. For example, mechanically pulverized particles are mostly at the micrometer scale, with an effective ingredient dissolution rate generally below 30%; while water levigation can reduce particle size to the submicrometer level, its yield is less than 15%, and it cannot achieve targeted removal of harmful impurities, thus failing to meet the modern Chinese medicine processing requirements of "high efficiency and low toxicity." Regarding technology adaptability, there is a significant discrepancy between existing liquid-phase exfoliation systems and the actual processing needs of natural mineral drugs. Currently used organic solvents (such as N-methylpyrrolidone) often have high toxicity, violating the fundamental principles of "green and safe" processing in Chinese medicine. At the auxiliary system level, existing exfoliation auxiliaries lack targeted design for the characteristics of natural mineral drugs. While conventional surfactants can improve the stability of the exfoliated products to some extent, they may have potential side effects on organisms, failing to meet the stringent safety requirements of the industrialization stage.
[0005] In general, existing technologies for processing mineral drugs suffer from the following problems: traditional processing techniques struggle to achieve both refined processing, efficient dissolution of active ingredients, and targeted toxicity reduction; they also suffer from low production efficiency and poor adaptability to large-scale production. The solvents (organic solvents) and auxiliary systems (surfactants) used in traditional liquid-phase exfoliation methods pose biosafety risks and lack compatibility with mineral drug components, easily damaging the structure of the active ingredients. Existing technologies lack specific optimized designs tailored to the characteristics of mineral drugs, resulting in poor product uniformity, wide particle size distribution, and a lack of mature continuous processes and equipment support, hindering industrialization. Summary of the Invention
[0006] Purpose of the invention: To address the problems existing in the prior art, this invention provides a method for preparing natural mineral drugs by small molecule acid-assisted liquid-phase ultrasonic exfoliation, achieving efficient, green, and controllable exfoliation of natural mineral drugs, and preparing exfoliated mineral drug products with high purity, uniform morphology, and excellent biocompatibility. This method is applicable to various types of natural mineral drugs.
[0007] Technical Solution: To achieve the above objectives, the present invention provides a method for the ultrasonic exfoliation of natural mineral drugs using a small molecule acid-assisted liquid phase, comprising the following steps:
[0008] (1) Pretreatment of raw natural mineral medicine: Weigh the raw natural mineral medicine powder, disperse it in an organic solvent, and perform static soaking treatment. After soaking, dry the solid natural mineral medicine for later use.
[0009] (2) Liquid phase ultrasonic exfoliation: The natural mineral drug and small molecule acid after the pretreatment in step (1) are added to a mixed solvent system of water and organic solvent in sequence. After the mixture is fully mixed and in contact, liquid phase ultrasonic exfoliation is performed. After the treatment is completed, the system is taken out and naturally cooled to room temperature.
[0010] (3) Product purification: Take the upper suspension of the mixed system after cooling in step (2), centrifuge and collect the bottom precipitate; after washing, collect the precipitate and dry it to obtain a high-purity exfoliated natural mineral drug product.
[0011] The natural mineral medicines include layered mineral medicines and non-layered mineral medicines; the layered mineral medicines include talc, montmorillonite, vermiculite, gold-like stone, and blue-like stone; the non-layered mineral medicines include gypsum, realgar, orpiment, cinnabar, mirabilite, native copper (such as pyrite), amethyst, ochre, red ochre, halloysite, stamenite, actinolite, and calcite.
[0012] The small molecule acid is an organic acid containing a phenolic hydroxyl group, selected from one or more of 2,3,4-trihydroxybenzoic acid (2,3,4-TA), 2,4,6-trihydroxybenzoic acid (2,4,6-TA), 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA), 4-hydroxybenzoic acid (4-HA), tannic acid (TA), caffeic acid, ferulic acid, salicylic acid, p-hydroxycinnamic acid, vanillic acid, syringic acid, and protocatechuic acid.
[0013] In step (1), the organic solvent is anhydrous N,N-dimethylformamide (DMF), and the static soaking treatment time is 5-10 days. After soaking, the upper DMF clear liquid is removed, and the remaining pyrite solid is transferred to a vacuum drying oven for drying and later use.
[0014] In this process, the pyrite pretreated in step (1) and the small molecule acid are added sequentially to a mixed solvent system of water and organic solvent in a molar ratio of 1:1 to 1:5.
[0015] As a preferred option, the molar ratio of natural mineral drug to small molecule acid in step (2) is 1:1.
[0016] In step (2), the mixed solvent system of water and organic solvent is a mixed solvent system of water and DMF, wherein the volume ratio of water to DMF is 10:1-5:1, and the ultrasonic power of the liquid phase ultrasonic stripping treatment in step (2) is 80~300 W, the ultrasonic temperature is 40~80℃, and the time is 1-3h.
[0017] In step (3), the upper suspension of the mixed system after cooling in step (2) is taken to remove the natural mineral raw materials that are not completely stripped; the collected supernatant is centrifuged at high speed to collect the bottom precipitate; ultrapure water is added to the precipitate to redisperse it, and the above centrifugation and washing operation is repeated 3-4 times. Finally, the precipitate is collected and dried under vacuum to obtain high-purity stripped pyrite product.
[0018] The drying described in steps (1) and (3) is vacuum drying, with the following conditions: drying temperature 30-80℃, drying time 6-48 h, and drying until the product reaches constant weight.
[0019] The natural mineral drug prepared by the method described in this invention. The product obtained by the small molecule acid-mediated exfoliation of this invention is a 5nm ultra-small nanosheet or a 60nm nanoplate, with uniform particle size, good dispersibility, increased specific surface area, high dissolution efficiency, and high drug utilization.
[0020] The particle size of the natural mineral drug is 40-200 μm.
[0021] The present invention utilizes the structural characteristics of different small molecule acids to directionally regulate the exfoliation morphology: 1. Different number of phenolic hydroxyl groups: 4-hydroxybenzoic acid (1 phenolic hydroxyl group) and 2,4,6-trihydroxybenzoic acid (3 symmetrically dispersed phenolic hydroxyl groups) have weak coordination, while gallic acid and tannic acid (polyphenolic hydroxyl groups) have strong coordination; 2. Different coordination binding abilities: weak coordination forms 60 nm nanoplatelets, while strong coordination, combined with ultrasonic shearing force, promotes the complete dissociation of particles into 5 nm ultra-small nanosheets. The corresponding small molecule acid can be selected according to the target size to achieve precise preparation.
[0022] This invention addresses the problems of complex processing techniques, low efficiency, and poor scalability in traditional mineral drug processing, as well as the high solvent toxicity and residual risks of traditional liquid-phase exfoliation methods. It establishes a simple, environmentally friendly ultrasonic liquid-phase exfoliation process system that improves processing efficiency while ensuring biocompatibility, providing core support for the industrialization of this technology. To address the safety hazards introduced by traditional auxiliary exfoliation systems, small-molecule weak acids derived from plant extracts, such as gallic acid and tannic acid, are selected as auxiliary agents. Leveraging their natural safety and mild reaction characteristics, a dedicated auxiliary exfoliation system is constructed to improve product biocompatibility, laying the foundation for biosafety in clinical translation. Furthermore, to address the issues of poor product uniformity and uncontrollable morphology obtained by traditional methods, the exfoliation process is precisely controlled by utilizing the coordination interaction between the phenolic hydroxyl groups in the small-molecule weak acids and metal ions such as Fe in the mineral drug, resulting in mineral drug products with uniform morphology and stable structure.
[0023] The method described in this invention is applicable to various natural mineral medicines, including but not limited to layered and non-layered mineral medicines. Layered mineral medicines can be selected from talc, montmorillonite, vermiculite, gold-like mineral, and blue-like mineral; non-layered mineral medicines can be selected from gypsum, realgar, orpiment, cinnabar, mirabilite, native copper, amethyst, ochre, red ochre, halloysite, stamenite, actinolite, and calcite. The specific implementation process is described in detail below using pyrite (FeS2) as a representative mineral medicine.
[0024] Pretreatment of natural mineral drugs: Select 10 mg of dried natural mineral drug powder (using pyrite as an example) with a particle size of 20-500 μm, and uniformly disperse it in 10 mL of anhydrous N,N-dimethylformamide (DMF). Transfer the powder to a sealed container for static soaking for 7 days. The swelling effect of DMF weakens the internal and interparticle forces of the mineral drug particles, laying the foundation for subsequent exfoliation. After soaking, remove the supernatant DMF solution and transfer the remaining solid mineral drug to a vacuum drying oven. Dry the product at 30-80℃ for 6-48 h until constant weight is achieved. Remove the residual DMF solvent, and seal the dried product for later use.
[0025] Small molecule acid-assisted liquid-phase ultrasonic exfoliation: The molar ratio of pretreated mineral drug to small molecule acid is 1:1. The corresponding mass of mineral drug solid and small molecule acid are weighed and added sequentially to a water / DMF mixed solvent system (where the volume ratio of water to DMF is 10:1-5:1, which can take into account both the dispersibility of mineral drug and the solubility of small molecule acid). The small molecule acid is an organic acid containing phenolic hydroxyl groups, specifically selected from one or more of 2,3,4-trihydroxybenzoic acid (2,3,4-TA), 2,4,6-trihydroxybenzoic acid (2,4,6-TA), 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA), 4-hydroxybenzoic acid (4-HA), tannic acid (TA), caffeic acid, ferulic acid, salicylic acid, p-hydroxycinnamic acid, vanillic acid, syringic acid, and protocatechuic acid. Directional exfoliation and morphology control are achieved by coordinating the phenolic hydroxyl groups with metal ions in the mineral drug.
[0026] The above-mentioned mixture was placed in a vortex oscillator and oscillated for 1-10 min to ensure thorough mixing and contact between the mineral drug and the small molecule acid. Then, it was transferred to a CNC ultrasonic cleaner with an ultrasonic power of 80-300 W and an ultrasonic temperature of 40-80℃ (this parameter range can balance the stripping efficiency and the stability of the effective components of the mineral drug, avoiding component damage caused by high temperature or high power). The constant temperature liquid phase ultrasonic stripping treatment was performed for 2 h. After the treatment, the system was removed and allowed to cool naturally to room temperature to obtain a mixed suspension containing the stripped mineral drug.
[0027] Product purification: After the cooled mixture is allowed to settle, the supernatant is removed and any incompletely separated lumpy mineral raw materials are quickly separated and removed. The collected supernatant is then transferred to a high-speed refrigerated centrifuge and the centrifuge speed is set to 14800 r / min. -1 Centrifuge for 10 min and collect the bottom precipitate. Add ultrapure water to the precipitate to redisperse it, and repeat the centrifugation and washing operation 3 times to thoroughly remove residual small molecule acids, DMF solvent and other impurities. Finally, transfer the purified precipitate to a vacuum drying oven and dry it at 30-80℃ for 6-48 h to constant weight to obtain a high-purity, uniformly morphologically exfoliated natural mineral drug product.
[0028] Key technical parameters and conditions: Types of natural mineral medicines: including layered structures (talc, montmorillonite, vermiculite, gold-bearing stone, blue-green stone) and non-layered structures (gypsum, realgar, orpiment, cinnabar, mirabilite, native copper, amethyst, ochre, red ochre, halloysite, stamenite, actinolite, calcite). The representative mineral medicine is pyrite (FeS2), which is a non-layered native copper.
[0029] Small molecule acid types: organic acids containing phenolic hydroxyl groups, selected from one or more of 2,3,4-trihydroxybenzoic acid, 2,4,6-trihydroxybenzoic acid, gallic acid (3,4,5-trihydroxybenzoic acid), 4-hydroxybenzoic acid, tannic acid, caffeic acid, ferulic acid, salicylic acid, p-hydroxycinnamic acid, vanillic acid, syringic acid, and protocatechuic acid.
[0030] Particle size of natural mineral pharmaceutical raw materials: 40-200 μm (pyrite is a representative example).
[0031] Soaking conditions: The solvent is anhydrous N,N-dimethylformamide (DMF), the volume is 10 mL (corresponding to 10 mg of mineral drug), the static soaking time is 7 days, and the soaking container must be sealed.
[0032] Drying conditions: Vacuum drying temperature 30-80℃, drying time 6-48 h, drying endpoint is constant weight of product.
[0033] Mixed solvent ratio: The volume ratio of water to DMF is 10:1-5:1.
[0034] Material ratio: The molar ratio of pretreated mineral drug to small molecule acid is 1:1.
[0035] Mixing conditions: vortex oscillation time 1~10 min.
[0036] Ultrasonic parameters: ultrasonic power 80~300 W, ultrasonic temperature 40~80℃, ultrasonic duration 2 h, ultrasonic equipment is an ultrasonic cleaner.
[0037] Centrifugation conditions: 14800 r·min -1 The centrifugation time was 10 minutes, and the equipment was a high-speed refrigerated centrifuge.
[0038] Cleaning conditions: redisperse the precipitate with ultrapure water, and repeat the centrifugation cleaning operation 3 times.
[0039] Final drying conditions: consistent with pretreatment drying (temperature 30-80℃, time 6-48 h, drying to constant weight).
[0040] Synergistic principle of process parameters: Pretreatment stage: The raw material particle size of 40-200 μm can ensure full penetration of DMF. 7-day static soaking can maximize the weakening of the internal forces of mineral drugs and avoid product morphology damage caused by uneven internal stress during subsequent exfoliation. Vacuum drying at 30-80℃ ensures complete removal of solvent and avoids degradation of heat-sensitive active ingredients.
[0041] The stripping stage: A water / DMF volume ratio of 10:1 to 5:1 can be adapted to the dispersion requirements of different hydrophilic and hydrophobic mineral drugs. The combination of 80-300 W ultrasonic power and 40-80℃ ultrasonic temperature achieves efficient stripping through cavitation effect and gentle shear force. At the same time, the phenolic hydroxyl groups of small molecule acids form coordination bonds with metal ions such as Fe in mineral drugs, inhibiting the aggregation of lamellae and regulating the morphology of the product. A 1:1 molar ratio can ensure that small molecule acids can fully play their intercalation and coordination roles, avoiding incomplete stripping due to insufficient dosage or residue due to excessive dosage.
[0042] Purification stage: 14800 r·min -1 High-speed centrifugation can quickly separate exfoliated nanosheets from impurities, three ultrapure water washes can thoroughly remove residual solvents and additives, and finally vacuum drying to constant weight ensures product purity and stability.
[0043] This invention preferably proposes a method for the liquid-phase ultrasonic exfoliation of natural mineral drugs assisted by small molecule acids, comprising: pretreating 40-200 μm natural mineral drugs with DMF, adding them to a water / DMF mixed solvent (volume ratio 10:1-5:1) with phenolic hydroxyl organic acids (such as gallic acid and tannic acid) at a molar ratio of 1:1, vortexing for 1-10 min, and then ultrasonically exfoliating at 80-300 W and 40-80℃ for 2 h, followed by centrifugation to purify the product. This method is green, safe, and simple, with controllable product morphology (5 nm ultra-small nanosheets or 60 nm nanoplatelets), achieving a maximum yield of 80.36%, and is applicable to various layered and non-layered natural mineral drugs, improving the consistency of drug efficacy.
[0044] Design principle of this invention:
[0045] 1. To address the issues of insufficient refinement and low dissolution rate in traditional mineral drug processing, the high toxicity of traditional liquid phase stripping solvents, and the inability of strong acid systems to strip components and their tendency to damage components, we selected small molecule acids containing phenolic hydroxyl groups derived from plant extracts as adjuvants. These adjuvants have both intercalation stripping and coordination regulation functions, while simultaneously meeting the requirements of biosafety and green processing of traditional Chinese medicine.
[0046] 2. Targeting the lattice structure characteristics of mineral drugs such as pyrite, a DMF solubilization pretreatment is first used to weaken the internal / inter-particle forces, lowering the subsequent exfoliation energy barrier. Then, small molecule acids react with metal ions (Fe) in the mineral drug. 2+ The specific coordination of ) enables targeted regulation of the exfoliation process, avoiding product heterogeneity caused by random exfoliation;
[0047] 3. Based on the structural loosening effect of solvent swelling pretreatment, the directional regulation effect of small molecule acid coordination, and the mild shearing effect of ultrasonic cavitation, the three factors work together to reduce the energy required for exfoliation, avoid the damage of high-power ultrasound to the crystal structure of mineral drugs, and achieve high-yield controllable exfoliation while preserving the complete crystal structure.
[0048] Reaction mechanism of this invention:
[0049] 1. Solvation and swelling effect of DMF pretreatment: Anhydrous DMF, used as a pretreatment solvent, penetrates into the interparticle spaces and lattice layers of minerals such as pyrite through solvation and swelling, weakening interlayer van der Waals forces and interparticle bonding forces, making the dense crystal structure more porous and exposing more active crystal faces. On the other hand, the carbonyl oxygen (C=O) in the DMF molecule carries a partial negative charge, which can react with the Fe in the minerals. 2+ The formation of weak coordination allows the electron cloud to shift from the DMF to the Fe. 2+ The d orbitals increase the electron density around Fe, further weakening the Fe-S bond strength and laying the structural foundation for subsequent coordination and ultrasonic exfoliation of small molecule acids.
[0050] 2. Coordination intercalation and size regulation of small molecule acids: Small molecule acids containing phenolic hydroxyl groups are the core regulatory units of this invention. The phenolic hydroxyl group (-OH) in their molecules interacts with Fe... 2+ Coordination occurs, simultaneously achieving intercalation exfoliation and morphology-oriented regulation. The regulatory effect is determined by the number of phenolic hydroxyl groups, substitution positions, and electron-withdrawing effects of the small molecule acid. The coordination structures of several small molecule acids with Fe are shown below. Figure 31 .
[0051] In this invention, the number and position of phenolic hydroxyl groups determine the coordination strength, and the electron-withdrawing effect affects the degree of lattice dissociation: the 4-HA group with one phenolic hydroxyl group has weak coordination, exhibiting a bicoordinated chain structure, and can only achieve slight exfoliation, resulting in a 60 nm nanoplate; the 2,4,6-TA group with three phenolic hydroxyl groups has weak coordination, exhibiting a bicoordinated chain structure, and can only achieve slight exfoliation, also resulting in a 60 nm nanoplate; the 2,3,4-TA and 3,4,5-TA groups with three phenolic hydroxyl groups have strong coordination, and the strong electron-withdrawing effect of asymmetric substitution results in more complete lattice dissociation, resulting in a 5 nm ultrasmall nanosheet; tannic acid (composed of five 3,4,5-TA fragments) also yields a 5 nm ultrasmall nanosheet due to the strong anchoring effect of the polyphenolic hydroxyl groups.
[0052] 3. Synergistic and Efficient Exfoliation through Ultrasonic Cavitation and Coordination: The synergistic effect of controlled ultrasound cavitation and the coordination intercalation of small molecule acids is key to achieving efficient exfoliation. Ultrasound generates numerous microbubbles in the solvent. When these bubbles burst, they release strong microjets and shear forces, exerting gentle mechanical shearing on the loosened mineral particles and breaking down the interparticle bonds. Meanwhile, the coordination intercalation of small molecule acids has already weakened the chemical bonds within the crystal lattice, significantly reducing the energy threshold required for exfoliation. This allows the shearing force of ultrasound to act efficiently on the interlayer space of the crystal lattice rather than simply breaking down particles.
[0053] 4. Coordination-mediated solution stability: Small molecule acids and Fe 2+ The coordination effect not only achieves exfoliation regulation but also provides coordination protection for the product. The phenolic hydroxyl / carboxyl groups and Fe... 2+ Forming stable coordination bonds, enabling Fe 2+ Keep d 6 Low-spin state, no unpaired electrons, avoids Fe 2+ Oxidized to Fe 3+ Meanwhile, directional coordination ensures the product has a complete crystal structure with no obvious S vacancies or lattice defects, which greatly improves the product's structural and storage stability.
[0054] The core advantages and practical benefits of this invention:
[0055] 1. Size controllable: Based on the structural characteristics of small molecule acids, products can be prepared in a directional manner from 5 nm ultra-small nanosheets or 60 nm nanoplates, with uniform particle size distribution and no obvious agglomeration. In contrast, traditional mechanical pulverization / flying methods produce products with a large particle size range (micrometer level) and no targeted control capability. Strong acid systems cannot achieve exfoliation at all. This advantage allows the products to be adapted to different drug formulation needs (such as nano-formulations and suspensions), improving the adaptability of drug dosage forms.
[0056] 2. Improved stripping efficiency and yield: The synergistic effect of ultrasonic cavitation and coordination intercalation results in a stripping yield of up to 80.36% (tannic acid system), which is much higher than the traditional water-milling method (≤15%) and mechanical pulverization method (dissolution rate ≤30%). Moreover, the structural characteristics of small molecule acids can achieve gradient control of yield to meet different production needs, greatly improve the industrial processing efficiency of natural mineral drugs, and reduce production time and raw material loss.
[0057] 3. Green and safe preparation process: The small molecule acids selected in this invention are derived from plant extracts (gallic acid, tannic acid, etc.), which have good biocompatibility and no toxic residues; the water / DMF mixed solvent system can be completely removed after centrifugation and washing, and DMF is only a pretreatment solvent, which is used in small amounts and is easy to remove. Compared with the traditional liquid phase stripping pure organic solvent system (NMP / DMF), it fully complies with the core concept of "green processing" of traditional Chinese medicine. The product can be directly used for drug research and development without additional detoxification / impurity removal steps, reducing the cost of clinical translation.
[0058] This invention, for the first time, utilizes plant-derived phenolic hydroxyl-containing small molecule acids as the core regulatory unit to construct a liquid-phase ultrasonic exfoliation process adapted to natural mineral drugs. By leveraging the specific coordination of small molecule acids with metal ions in mineral drugs, it achieves green, efficient, and precisely controllable morphology / size exfoliation of natural mineral drugs, while simultaneously considering product structural stability and adhering to the core concept of "green processing" in traditional Chinese medicine. Compared to traditional mineral drug processing techniques (mechanical pulverization, water-milling), this invention overcomes the limitations of extensive processing, solving problems such as product heterogeneity, low dissolution rate of active ingredients, and poor yield, achieving refined and targeted processing. Compared to traditional liquid-phase exfoliation methods, it abandons highly toxic organic solvent systems and uses plant-derived small molecule acids and low-toxicity mixed solvents, solving the problems of toxicity residues and lack of targeted regulation, meeting the safety requirements of traditional Chinese medicine processing. This invention extends existing liquid-phase exfoliation technologies to the field of natural mineral drugs, achieving, for the first time, multiple regulation of product morphology, yield, and stability. Its applicability is expected to cover various layered and non-layered natural mineral drugs, better meeting industrialization needs.
[0059] This invention is the first to apply plant-derived phenolic hydroxyl-containing small molecule acids to the liquid-phase exfoliation of natural mineral drugs, achieving a dual combination of exfoliation regulation and biological green safety, unlike traditional exfoliation aids that only improve exfoliation efficiency. It is also the first to propose an electron-withdrawing effect based on the number and substitution position of phenolic hydroxyl groups in small molecule acids to anchor Fe atoms, and based on the difference between monodentate and bidentate coordination modes, to achieve directional regulation of the exfoliation process of natural mineral drugs, resulting in controllable product size, complete product crystal structure, and high solution stability.
[0060] In this invention, the synergistic effect of solvation swelling and weak coordination not only loosens the dense crystal structure of the mineral drug and exposes the active crystal facets, but also weakens the Fe-S bond strength, thus significantly reducing the energy threshold for subsequent exfoliation. The coordination intercalation of small molecule acids and the shear force of ultrasonic cavitation work together, with coordination intercalation weakening the forces inside the crystal lattice in advance, and the ultrasonic shear force acting precisely on the interlayer to achieve efficient exfoliation, avoiding the damage to the crystal structure caused by high-power ultrasound and preserving the complete crystal structure.
[0061] This invention utilizes the differences in the structure (number and substitution position) of phenolic hydroxyl groups in small molecule acids containing phenolic hydroxyl groups, which lead to differences in electron-withdrawing effects. Through their coordination with Fe ions in mineral drugs, the morphology and size of the exfoliated products of natural mineral drugs can be precisely controlled. Coordination is the core driving force for controlling the characteristics of the products.
[0062] The key design of this invention is the precise selection of small molecule acids containing phenolic hydroxyl groups. Their structural differences directly determine the coordination mode and binding strength with Fe ions, which in turn directly leads to significant differences in the morphology (from 5 nm ultra-small nanosheets to 60 nm nanoplatelets) and size of the products. This is the core key to achieving directional preparation.
[0063] Beneficial effects: Compared with the prior art, the present invention has the following advantages:
[0064] (1) Using plant extracts containing phenolic hydroxyl small molecule acids (such as gallic acid and tannic acid) as adjuvants, the biosafety is high and there is no risk of solvent residue. Compared with traditional mineral drug processing technology (yield ≤15%) and strong acid system (cannot be stripped), the product yield reaches up to 80.36%, which greatly improves the processing efficiency of natural mineral drugs.
[0065] (2) Directional exfoliation is achieved through coordination between small molecule acids and metal ions such as Fe ions. The product has a uniform morphology (5 nm ultra-small nanosheets or 60 nm nanoplates can be controlled), complete crystal structure without obvious defects, and Fe exists stably in a low spin state, ensuring consistent efficacy.
[0066] (3) It is applicable to a variety of natural mineral medicines, both layered and non-layered (such as talc, realgar, gypsum, etc.). The process steps are simple and the parameters are controllable. It takes into account the concept of "green processing" and the potential for continuous production, and solves the core pain points of insufficient refinement of traditional processes and destruction of components by strong acid systems. Attached Figure Description
[0067] Figure 1 The images shown are TEM images and elemental (Fe, S) diffraction mapping images of natural pyrite used in Example 1 of this invention.
[0068] Figure 2 AC-TEM image of natural pyrite used in Example 1 of this invention;
[0069] Figure 3 The image shows a magnified AC-TEM view (left) of the natural pyrite used in Example 1 of this invention and the corresponding three-dimensional surface intensity distribution (right).
[0070] Figure 4The images show a SEM image (left) and a magnified SEM image (right) of the natural pyrite used in Example 1 of this invention.
[0071] Figure 5 This is a statistical diagram showing the particle size distribution of natural pyrite used in Example 1 of the present invention;
[0072] Figure 6 The images show the SEM image (left) and a magnified SEM image (right) of Pyrite (Pyrite-DMF) after DMF preprocessing in Embodiment 1 of the present invention.
[0073] Figure 7 This is a statistical diagram of the particle size distribution of Pyrite (Pyrite-DMF) after DMF pretreatment in Example 1 of the present invention;
[0074] Figure 8 The small molecule weak acids used in the reaction process of Example 1 of this invention include 2,3,4-trihydroxybenzoic acid (2,3,4-TA), 2,4,6-trihydroxybenzoic acid (2,4,6-TA), 3,4,5-trihydroxybenzoic acid (3,4,5-TA), 4-hydroxybenzoic acid (4-HA), and tannic acid (TA);
[0075] Figure 9 This is a photograph of the reaction product in Example 1 of this invention;
[0076] Figure 10 The diagrams (top view and side view) show the structure of the reaction product in Example 1 of this invention.
[0077] Figure 11 The image shows the AC-TEM images of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention, along with a magnified view of a portion of the AC-TEM image and the corresponding three-dimensional surface intensity distribution.
[0078] Figure 12 The yields of different reaction products in Example 1 of this invention;
[0079] Figure 13 The ultraviolet absorption spectra of the small molecule acids (2,3,4-TA, 2,4,6-TA, 3,4,5-TA, 4-HA, TA) used in Example 1 of this invention are shown (left image 200-1000 nm, right partial magnified image 400-800 nm).
[0080] Figure 14The ultraviolet absorption spectra of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention are shown in the left figure (200-1000 nm, right partial magnified figure (400-800 nm).
[0081] Figure 15 The infrared spectra of natural pyrite and DMF-pretreated pyrite (Pyrite-DMF) used in Example 1 of this invention are shown.
[0082] Figure 16 Infrared spectra of the small molecule acids (2,3,4-TA, 2,4,6-TA, 3,4,5-TA, 4-HA, TA) used in Example 1 of this invention;
[0083] Figure 17 The infrared spectra of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention are shown.
[0084] Figure 18 Raman spectra of natural pyrite and DMF-pretreated pyrite (Pyrite-DMF) used in Example 1 of this invention;
[0085] Figure 19 Raman spectra of the small molecule acids (2,3,4-TA, 2,4,6-TA, 3,4,5-TA, 4-HA, TA) used in Example 1 of this invention;
[0086] Figure 20 The Raman spectra of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention are shown.
[0087] Figure 21 The X-ray diffraction patterns of natural pyrite and DMF-pretreated pyrite (Pyrite-DMF) used in Example 1 of this invention are shown.
[0088] Figure 22 The X-ray diffraction pattern of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention;
[0089] Figure 23The X-ray photoelectron spectra of natural pyrite and DMF-pretreated pyrite (Pyrite-DMF) used in Example 1 of this invention are shown (from left to right: full spectrum, Fe 2p narrow spectrum, S 2p narrow spectrum).
[0090] Figure 24 The X-ray photoelectron spectra of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention are shown (from left to right: full spectrum, Fe 2p narrow spectrum, S 2p narrow spectrum).
[0091] Figure 25 The electron spin resonance spectra of natural pyrite and DMF-pretreated pyrite (Pyrite-DMF) used in Example 1 of this invention are shown.
[0092] Figure 26 The electron spin resonance spectra of the small molecule acids (2,3,4-TA, 2,4,6-TA, 3,4,5-TA, 4-HA, TA) used in Example 1 of this invention are shown.
[0093] Figure 27 The electron spin resonance spectra of the reaction products (2,3,4-TAP, 2,4,6-TAP, 3,4,5-TAP, 4-HAP, TAP) in Example 1 of this invention are shown.
[0094] Figure 28 This is a photograph of the reaction product of Comparative Example 1 in this invention.
[0095] Figure 29 The yields of different reaction products in Comparative Example 2 of this invention;
[0096] Figure 30 These are TEM images of different reaction products from Comparative Example 2 in this invention;
[0097] Figure 31 These are the coordination structures of several small molecule acids with Fe. Detailed Implementation
[0098] Unless otherwise specified, all materials and reagents used in the following examples are commercially available. Experimental methods not specifically described in the examples are generally performed under standard conditions or as recommended by the manufacturer.
[0099] Experimental materials
[0100] Natural mineral medicine: Primitive pyrite (FeS2) powder, with a particle size of 40-200 μm, used in a dry state. Its main elemental composition is Fe and S, and its crystal structure is complete and dense.
[0101] Solvents: anhydrous N,N-dimethylformamide (DMF, purity ≥99.5%), ultrapure water (resistivity ≥18.2 MΩ·cm);
[0102] Small molecule acids: 2,3,4-trihydroxybenzoic acid (2,3,4-TA), 2,4,6-trihydroxybenzoic acid (2,4,6-TA), 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA), 4-hydroxybenzoic acid (4-HA), and tannic acid (TA), all of which are analytical grade. Tannic acid contains five 3,4,5-trihydroxybenzoic acid fragments.
[0103] Experimental equipment
[0104] Ultrasonic cleaner (power adjustment range 0-300 W, temperature adjustment range 20-100℃).
[0105] Ultrasonic crusher (800 W, 20 kHz)
[0106] High-speed refrigerated centrifuge (maximum speed ≥15000 r·min) -1 );
[0107] Vacuum drying oven (temperature adjustment range 20-120℃, vacuum degree ≤-0.095 MPa);
[0108] Vortex oscillator (oscillation frequency 0-3000 r·min) -1 );
[0109] Electronic balance (accuracy 0.01 mg);
[0110] Characterization equipment: Scanning electron microscope (SEM), X-ray diffractometer (XRD), laser particle size analyzer.
[0111] Example 1
[0112] 1. Pretreatment of natural mineral drugs
[0113] Select dry pyrite powder with a particle size of 40-200 μm, accurately weigh 10 mg using an electronic balance, and slowly add it to a sealed container containing 10 mL of anhydrous DMF. Use a vortex shaker to initially shake for 3 min to ensure that the pyrite powder is evenly dispersed in the DMF and to avoid particle agglomeration.
[0114] The sealed container was placed in a room temperature environment for static immersion treatment for 7 days. During this process, DMF penetrated into the interior of the pyrite particles and the gaps between the particles through the swelling effect between the solvent and solute, weakening the internal forces and interparticle bonding forces, thus reducing the energy barrier and laying the structural foundation for the subsequent ultrasonic exfoliation process.
[0115] After soaking, the clear DMF supernatant was carefully removed by pouring, ensuring that no residual pyrite solids were carried away. The remaining pyrite solids were then transferred to a clean petri dish and placed in a vacuum drying oven at 60°C for 24 hours until constant weight was achieved, completely removing any residual DMF solvent. After drying, the pretreated pyrite solids were sealed and stored for later use.
[0116] 2. Small molecule acid-assisted liquid-phase ultrasonic exfoliation
[0117] Using a molar ratio of 1:1, pretreated pyrite (0.1 mmol) and a small molecule acid (0.1 mmol) were weighed separately using an electronic balance. The corresponding masses of pyrite solid and the target small molecule acid (one of 2,3,4-TA, 2,4,6-TA, gallic acid, 4-HA, or TA in this embodiment can be selected) were added sequentially to a pre-prepared water / DMF mixed solvent system (10 mL). The volume ratio of water to DMF was 10:1. This ratio was optimized to simultaneously ensure the dispersibility of pyrite and the solubility of the small molecule acid, avoiding a decrease in stripping efficiency or precipitation of the small molecule acid due to improper solvent ratio.
[0118] The small molecule acids are all organic acids containing phenolic hydroxyl groups. The phenolic hydroxyl groups in their molecular structure can form coordination bonds with Fe ions in pyrite. On the one hand, they further weaken the internal forces of pyrite through intercalation, and on the other hand, they regulate the growth direction of the lamellar layers during the exfoliation process through coordination, thereby achieving directional exfoliation and uniformity of product morphology.
[0119] The above-mentioned mixture was transferred to a vortex oscillator and the oscillation time was set to 5 min to allow the pyrite solid and the small molecule acid to be fully mixed and contacted in the mixed solvent to form a uniformly dispersed suspension. The suspension was then transferred to a CNC ultrasonic cleaner and the ultrasonic power was set to 200 W and the ultrasonic temperature to 50℃. This parameter range has been experimentally verified to balance the stripping efficiency and the stability of the effective components of pyrite, and to avoid the destruction of mineral components and structural phase transformation caused by excessive power or temperature.
[0120] An ultrasonic device was activated to perform isothermal liquid-phase ultrasonic exfoliation, with the ultrasonic duration strictly controlled to 2 hours. During the ultrasonic process, the shear force generated by cavitation effect and the coordination intercalation of small molecule acids synergistically achieved efficient exfoliation of pyrite particles. After the treatment, the ultrasonic device was turned off, and the system was removed and allowed to cool naturally to room temperature, yielding a mixed suspension containing exfoliated pyrite.
[0121] 3. Product purification
[0122] After cooling, the mixed suspension was allowed to settle at room temperature for 10 minutes to allow the incompletely stripped lumpy pyrite raw material to settle to the bottom of the container. The upper suspension was carefully removed using a pipette, and the incompletely stripped lumpy raw material was quickly separated and removed. The supernatant containing stripped pyrite was collected.
[0123] The collected supernatant was transferred to centrifuge tubes in a high-speed centrifuge, and the centrifuge speed was set to 14800 r·min. -1 Centrifuge for 10 min to allow the exfoliated pyrite nanosheets to settle to the bottom of the centrifuge tube, and collect the bottom precipitate.
[0124] Add 5 mL of ultrapure water to the above precipitate, redisperse the precipitate using a vortex mixer, and repeat the process at 14800 r·min. -1 Centrifuge for 10 min, repeat the above operation 3 times to thoroughly remove residual small molecule acids, DMF solvent and other impurities from the precipitate.
[0125] Finally, the purified precipitate was transferred to a vacuum drying oven, and the drying temperature was set to 60℃ and the drying time was set to 24 h. The product was dried until it reached a constant weight, and high-purity, uniformly morphological nano-sized pyrite drug was obtained.
[0126] Comparative Example 1
[0127] Step 1 is the same as Step 1 in Example 1.
[0128] 2. Strong acid-assisted liquid-phase ultrasonic exfoliation
[0129] To compare the exfoliation effects of strong acid and the phenolic hydroxyl-containing small molecule acid of the present invention, this comparative example uses strong acid instead of small molecule acid, and the remaining experimental conditions are completely consistent with those of Example 1, as follows:
[0130] Using a molar ratio of 1:1, pretreated pyrite (0.1 mmol) and a small molecule acid (0.1 mmol) were weighed separately using an electronic balance. The corresponding masses of pyrite solid and the target strong acid (one of 0.1 M acetic acid, 0.1 M nitric acid, or 0.1 M hydrochloric acid can be selected in this comparative example) were added sequentially to a pre-prepared water / DMF mixed solvent system (10 mL). The volume ratio of water to DMF was 10:1, consistent with Example 1.
[0131] The strong acids do not contain phenolic hydroxyl groups; their molecular structures contain only hydrogen ions and acid radicals. They cannot form coordination bonds with Fe ions in pyrite. They can only react non-specifically with the surface of pyrite through a strongly acidic environment. They cannot produce intercalation to weaken the internal forces of pyrite, nor can they regulate the direction of lamellar growth through coordination. Therefore, they do not have the ability to perform directional exfoliation and morphology control.
[0132] The above-mentioned mixture was transferred to a vortex oscillator and the oscillation time was set to 5 min to allow the pyrite solid and strong acid to be fully mixed and contacted in the mixed solvent. Then the suspension was transferred to a CNC ultrasonic cleaner and the ultrasonic power was set to 200 W and the ultrasonic temperature to 50°C, which were completely consistent with the ultrasonic parameters in Example 1. The ultrasonic equipment was started to perform isothermal liquid phase ultrasonic stripping treatment, and the ultrasonic duration was strictly controlled to 2 h.
[0133] After the treatment was completed, the ultrasonic equipment was turned off, and the system was taken out and allowed to cool naturally to room temperature. It was observed that no obvious suspension was formed in the mixed system, and only unpeeled blocky pyrite particles were present. No peeled pyrite products were collected after centrifugation and purification.
[0134] The results confirmed that strong acids, lacking the synergistic effect of phenolic hydroxyl groups coordinating with Fe ions, and the strong acidic environment easily leading to oxidation of the pyrite surface or localized structural damage, could not effectively strip the natural mineral drug. This contrasts sharply with the highly efficient stripping effect assisted by small molecule acids in Example 1. Replacing the small molecule acids containing phenolic hydroxyl groups with 0.1 M strong acids (acetic acid, nitric acid, hydrochloric acid) failed to achieve mineral drug stripping because the absence of phenolic hydroxyl groups prevented coordination with Fe ions.
[0135] Comparative Example 2
[0136] 1. Step 1 is the same as step 1 in Example 1.
[0137] 2. Small molecule acid-assisted liquid-phase ultrasonic exfoliation
[0138] Using a molar ratio of 1:1, pretreated pyrite (0.1 mmol) and a small molecule acid (0.1 mmol) were weighed separately using an electronic balance. The corresponding masses of pyrite solid and the target small molecule acid (one of 2,3,4-TA, 2,4,6-TA, gallic acid, 4-HA, or TA in this embodiment can be selected) were added sequentially to a pre-prepared water / DMF mixed solvent system (10 mL). The volume ratio of water to DMF was 10:1. This ratio was optimized to simultaneously ensure the dispersibility of pyrite and the solubility of the small molecule acid, avoiding a decrease in stripping efficiency or precipitation of the small molecule acid due to improper solvent ratio.
[0139] The small molecule acids are all organic acids containing phenolic hydroxyl groups. The phenolic hydroxyl groups in their molecular structure can form coordination bonds with Fe ions in pyrite. On the one hand, they further weaken the internal forces of pyrite through intercalation, and on the other hand, they regulate the growth direction of the lamellar layers during the exfoliation process through coordination, thereby achieving directional exfoliation and uniformity of product morphology.
[0140] The above-mentioned mixture was transferred to a vortex oscillator and the oscillation time was set to 5 min to allow the pyrite solid and the small molecule acid to be fully mixed and contacted in the mixed solvent to form a uniformly dispersed suspension. The suspension was then transferred to an ultrasonic crusher and the ultrasonic power was set to 800 W, the ultrasonic frequency to 20 Hz, and the ultrasonic temperature to 50℃. This parameter range has been experimentally verified to balance the stripping efficiency and the stability of the effective components of pyrite, and to avoid the destruction of mineral components and structural phase transformation caused by excessive power or temperature.
[0141] An ultrasonic crusher was used for isothermal liquid-phase ultrasonic exfoliation treatment, with the ultrasonic duration strictly controlled to 2 hours. During the ultrasonic process, the shear force generated by cavitation effect and the coordination intercalation of small molecule acids synergistically achieved efficient exfoliation of pyrite particles. After treatment, the ultrasonic equipment was turned off, and the system was removed and allowed to cool naturally to room temperature, yielding a mixed suspension containing exfoliated pyrite.
[0142] Step 3 is the same as step 3 in Example 1.
[0143] The results confirmed that replacing the CNC ultrasonic cleaner with an ultrasonic disruptor did not significantly improve the product yield or change the sample size. This is because the power of the CNC ultrasonic cleaner was sufficient to meet the requirements of coordination-mediated stripping, and simply increasing the ultrasonic power / intensity could not change the product morphology and size control results dominated by coordination.
[0144] Experimental Example 1
[0145] This invention systematically characterized the raw material properties, pretreatment effects, small molecule acid structures, and morphological structures of the natural mineral drug pyrite (FeS2) prepared in Example 1, Comparative Example 1, and Comparative Example 2. The specific results are as follows:
[0146] As shown in Figure 1, the pyrite raw material selected in this invention is mainly composed of Fe and S elements, with no obvious impurity elements; scanning electron microscopy (SEM) characterization shows that the original pyrite particle size is at the micrometer level (Figure 2), and the crystallinity is good. X-ray diffraction (XRD) pattern confirms ( Figure 3 The interplanar spacing of the pyrite is 0.27 nm, consistent with the characteristic diffraction peaks of the standard pyrite (200) crystal plane, indicating that the raw material has a complete and dense crystal structure. Due to the close packing of crystal particles, the raw pyrite powder exhibits extremely low porosity and a dense structure (Figure 4), with an average particle size of 92.09 ± 20.42 μm (Figure 5). After static soaking in anhydrous N,N-dimethylformamide (DMF) for 7 days, the pyrite exhibits a loose and porous microstructure, macroscopically displaying a rough, frosted texture. DMF penetrates into the interior of pyrite particles through the swelling effect between the solvent and solute, effectively weakening the interlayer bonding force and promoting the dissociation of the particle structure. The layered structure extends inward, and the layered structure can be clearly observed in the magnified SEM image (Figure 6). The particle size analysis results show that the average particle size of pyrite increased to 104.27±16.91 μm after soaking (Figure 7), and the calculated swelling rate was 13.23%, which confirms that DMF pretreatment can effectively improve the looseness of the pyrite structure and lay the foundation for subsequent stripping.
[0147] Figure 8 shows the molecular structures of the five small-molecule acids used in this invention, including three positionally isomers of trihydroxybenzoic acid (2,3,4-trihydroxybenzoic acid, 2,4,6-trihydroxybenzoic acid, and 3,4,5-trihydroxybenzoic acid (gallic acid), each containing three hydroxyl groups and one carboxyl group on its benzene ring), 4-hydroxybenzoic acid (containing one hydroxyl group and one carboxyl group on its benzene ring), and tannic acid (containing five 3,4,5-trihydroxybenzoic acid fragments in its molecular structure). The pyrite product obtained by liquid-phase ultrasonic exfoliation with the above small-molecule acids is shown in Figure 9. The product is uniformly dark brown with no obvious unexfoliated lumps, indicating that the exfoliation process is uniform and effective. Figure 10 shows a simulated crystal structure of the exfoliated product (top and side views), showing that the product retains the original complete crystal structure of pyrite without lattice distortion due to the exfoliation process. The results of double aberration-corrected transmission electron microscopy (AC-TEM) (Figure 11) show that the size and morphology of the exfoliated products can be precisely controlled by the number of phenolic hydroxyl groups in the small molecule acids and the strength of the electron-withdrawing effect. Among them, the products of 4-hydroxybenzoic acid (4-HA) and 2,4,6-trihydroxybenzoic acid (2,4,6-TA) assisted exfoliation are nanoplates with a size of about 60 nm, and the products of 2,3,4-trihydroxybenzoic acid (2,3,4-TA) and 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA) assisted exfoliation are ultra-small nanosheets with a size of about 5 nm. All of the above products show a clear atomic lattice arrangement, with clearly visible atomic pillars and excellent crystallinity. Tannic acid (TA) contains more phenolic hydroxyl groups in its molecule, and has a stronger anchoring and binding ability with Fe atoms in pyrite. Its assisted exfoliation products are also ultra-small nanosheets with a size of about 5 nm, but the atomic structure arrangement is slightly damaged, showing disordered three-dimensional surface intensity distribution. The product yield varies depending on the small molecule acid-assisted stripping process. Figure 12 Specifically, the yields of the products in the 2,3,4-trihydroxybenzoic acid system (2,3,4-TAP) were 77.62%, 2,4,6-trihydroxybenzoic acid system (2,4,6-TAP) were 56.46%, 3,4,5-trihydroxybenzoic acid system (3,4,5-TAP) were 79.04%, 4-hydroxybenzoic acid system (4-HAP) were 13.49%, and tannic acid system (TAP) were 80.36%. These results further confirm that the structural characteristics of small molecule acids (number of phenolic hydroxyl groups and substitution positions) have a significant regulatory effect on the exfoliation efficiency.
[0148] The characterization results of ultraviolet-visible absorption spectroscopy (UV-Vis) are as follows: Figure 13-14 As shown: Figure 13The UV-Vis spectra of five small molecule acids are shown individually. All five acids exhibit a distinct characteristic absorption peak at 300 nm, corresponding to the phenolic hydroxyl and carboxyl groups. Electron transition; Figure 14 The UV-Vis spectra of the stripping products show that, in addition to inheriting the characteristic absorption peak of the small molecule acid at 300 nm (confirming a stable bond between the small molecule acid and pyrite), a broad characteristic absorption peak of FeS2 is observed in the 400-800 nm band, indicating that the products retain the intrinsic optical properties of pyrite. Notably, the 2,4,6-trihydroxybenzoic acid system product (2,4,6-TA-P) and the tannic acid system product (TAP) exhibit characteristic bulging peaks in the 480-520 nm band. These peaks originate from ligand-to-metal charge transfer transitions (LMCT), where electrons transfer from the π orbitals of the small molecule acid ligands to the d orbitals of Fe atoms in pyrite. This process requires the absorption of photons of specific wavelengths, further confirming the existence of coordination interactions between the small molecule acid and Fe atoms.
[0149] FTIR spectroscopy is used to characterize the coordination mechanism between small molecule acids and pyrite. Figure 15 The FTIR spectra of raw pyrite powder and pyrite after DMF pretreatment are shown. No characteristic peaks related to small molecule acids were observed, thus eliminating interference from impurities. Figure 16 The FTIR spectra of five small molecule acids are shown, with the most prominent feature being the C=O stretching vibration peak of the carboxyl group (-COOH), specifically at wavenumbers of: 2,3,4-trihydroxybenzoic acid (2,3,4-TA) 1670 cm⁻¹. -1 2,4,6-Trihydroxybenzoic acid (2,4,6-TA) 1660 cm -1 3,4,5-Trihydroxybenzoic acid (gallic acid, 3,4,5-TA) 1670 cm -1 4-Hydroxybenzoic acid (4-HA) 1665 cm -1 Tannic acid (TA) 1668 cm -1 . Figure 17 The FTIR spectra of the exfoliated products show that after coordination of the small molecule acid with Fe atoms, the C=O stretching vibration peaks shift to lower wavenumbers. This is due to the electron-withdrawing effect of the Fe atom's d orbitals, which reduces the electron cloud density and weakens the bond energy of the C=O bond in the carboxyl group. Different small molecule acids exhibit different coordination modes with Fe: 2,3,4-TAP shows a peak at 1669 cm⁻¹. -1 and 1631 cm -1 The appearance of a double absorption peak at 1625 cm⁻¹ indicates that it binds to Fe via a bidentate coordination mode; 2,4,6-TAP shows a peak at 1625 cm⁻¹. -1 A single absorption peak appears at 1660 cm⁻¹, corresponding to symmetrically distributed carboxyl groups forming monodentate coordination with Fe; 3,4,5-TAP shows an absorption peak at 1660 cm⁻¹.-1 and 1633 cm -1 The 4-HAP exhibits a double absorption peak, also indicating a bidentate coordination mode; the C=O stretching vibration peak shifts to 1658 cm⁻¹. -1 The TAP molecules exhibit monodentate coordination; due to the coordinated coordination of multiple carboxyl groups in the molecule, the C=O stretching vibration peak is broadened and shifted to 1642 cm⁻¹. -1 This is consistent with the coordination pattern analysis described above.
[0150] Raman spectroscopy characterization is used for in-depth analysis of pyrite structural changes and the coordination mechanism between small molecule acids and Fe atoms. Figure 18 The Raman spectrum of pyrite powder after DMF pretreatment is shown, with the 338 cm⁻¹ value being the highest. -1 and 370cm -1 The characteristic peaks at these locations correspond to the Eg (in-plane vibration mode) and Ag (out-of-plane vibration mode) of pyrite (FeS2), respectively. After DMF processing, both vibration peaks shifted to a lower wavenumber at 336 cm⁻¹. -1 and 368 cm -1 The reason is that the carbonyl oxygen (C=O) in the DMF molecule carries a partial negative charge, which reacts with the Fe on the surface of pyrite. 2+ The formation of weak coordination causes a portion of the electron cloud of DMF to transfer to the Fe atom, resulting in an increase in the electron density around Fe, which in turn weakens the vibrational energy barrier of the Fe-S bond and causes a shift in the peak position. Figure 19 The Raman spectra of five small molecule acids can be divided into four categories based on their characteristic vibrational peaks: (1) 258 cm⁻¹ -1 245 cm -1 270 cm -1 The peak at this position corresponds to the out-of-plane vibration of the benzene ring. Among them, the 2,4,6-TA peak has the lowest position (245 cm⁻¹) due to the highly symmetrical substitution distribution of the hydroxyl groups on the benzene ring and the uniform electron cloud distribution. -1 ); Due to the asymmetric substitution of hydroxyl groups, 2,3,4-TA and 3,4,5-TA exhibit uneven electron cloud density distribution. Their out-of-plane vibrational peaks are affected by the non-cooperative spatial and electronic effects of the substituents, resulting in wavenumbers higher than their symmetrically substituted homologues (258 cm⁻¹, respectively). -1 and 270 cm -1 (2) 341 cm -1 / 393 cm -1 356 cm -1 / 388 cm -1 The peak at 300-400 cm⁻¹ corresponds to the bending vibration of the benzene ring and the hydroxyl group (-OH). The asymmetric electron cloud density distribution causes a significant change in this vibrational mode, particularly in the 300-400 cm⁻¹ range. -1Characteristic peaks appeared in the band; among them, the carboxyl group and the adjacent hydroxyl group in 2,3,4-TA have steric hindrance, which makes the intensity of this characteristic peak significantly higher than that of other small molecule acids, while 2,4,6-TA has a highly symmetrical structure, and the bending vibration characteristics in this band are not obvious, so no obvious characteristic peaks appeared. (3) 520 cm -1 ,
[0151] 551 cm -1 The peak at this point corresponds to the in-plane vibration of the benzene ring. Disordered electron cloud distribution interferes with the stability of this vibration. Therefore, 2,3,4-TA does not exhibit a characteristic peak in this band, while 2,4,6-TA, due to the structural stability brought about by symmetric substitution, shows a high-intensity, high-stability in-plane vibration peak (551 cm⁻¹). -1 (4) 1336 cm -1 1263 cm -1 1322 cm -1 The peak at 1654 cm⁻¹ corresponds to the CO bond stretching vibration. -1 1596 cm -1 1613 cm -1 The peak at 1654 cm⁻¹ corresponds to the C=O bond stretching vibration; the symmetric vibration mode of 2,4,6-TA is Raman inactive due to zero change in polarizability, and no characteristic peak of C=O bond stretching vibration is observed; in 2,3,4-TA, the spatial distance between the groups is relatively close, and the electron cloud is concentrated on one side of the benzene ring, only reaching a peak at 1654 cm⁻¹. -1 A single C=O stretching vibration peak appears at this location. Figure 20 The Raman spectrum of the exfoliated product shows that the 3,4,5-TA complex with Fe (3,4,5-TAP) is at 592 cm⁻¹. -1 1334 cm -1 1484 cm -1 The classic characteristic bands of the complexed products appeared at the spectral density. In all products, the C=O bonds of the small molecule acids underwent electron cloud rearrangement due to coordination, and their stretching vibration characteristic peaks disappeared. The new peaks that replaced them corresponded to the coordination bond vibrations formed between Fe and the carboxyl group, confirming the occurrence of the complexation reaction. 2,3,4-TA complexed with Fe in a bidentate coordination mode. This coordination mode significantly reduced the polarizability changes during molecular vibration, strongly suppressing the Raman scattering signal; therefore, 2,3,4-TAP had no obvious characteristic peaks. Furthermore, when Fe complexed with ligands, both bidentate and monodentate coordination modes enhanced molecular planarity, restricting out-of-plane vibrations of the benzene ring (manifested as the disappearance of the benzene ring out-of-plane vibration characteristic peaks in the product spectra), while in-plane vibrations of the benzene ring could still generate signals (e.g., 2,4,6-TAP at 517 cm⁻¹). -1 3,4,5-TAP at 519 cm -1The peak at the location further confirms that the small molecule acid forms a stable coordination with the Fe atoms in pyrite through the phenolic hydroxyl group, successfully achieving the directional stripping of the mineral drug.
[0152] To further clarify the crystal structure and electronic state characteristics of the product, X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), and electron spin resonance (ESR) spectroscopy were used for systematic characterization. Figure 21 The XRD patterns of pristine pyrite and pyrite-DMF pretreated pyrite are shown. Both exhibit typical pyrite crystal structures, with clear diffraction peaks at the corresponding (200) crystal planes, confirming that the DMF pretreatment did not destroy the intrinsic crystal structure of pyrite. Notably, the diffraction intensity of the (200) crystal plane was significantly enhanced after DMF treatment. This is presumably because the solvation effect of DMF penetrates into the interlayer of the crystal, causing interlayer dissociation and exposing more (200) crystal planes, resulting in enhanced diffraction signals. Figure 22 XRD patterns of the products exfoliated with small molecule acids were shown. The results revealed that the coordination structure of the small molecule acids with Fe significantly modulates the diffraction intensity of the (200) crystal plane of pyrite: the product of the 3,4,5-trihydroxybenzoic acid system (3,4,5-TAP) had the lowest diffraction intensity on the (200) crystal plane (relative intensity 149); while the product of the 2,4,6-trihydroxybenzoic acid system (2,4,6-TAP) had a higher diffraction intensity (relative intensity 1120). This phenomenon is closely related to the electron-withdrawing effect of small molecule acids. The electron-withdrawing characteristics of small molecule acids can synergistically enhance the exfoliation effect, further promote the dissociation of the crystal structure, and thus reduce the diffraction intensity of the (200) crystal plane. The lower the diffraction intensity, the deeper the degree of dissociation between crystal layers and the more significant the exfoliation effect. Figure 23 XPS spectra of Fe 2p orbitals in pristine pyrite and Pyrite-DMF. Compared to untreated pristine pyrite powder, the Fe 2p orbital binding energy shifts to lower energies by 0.2 eV after DMF pretreatment. This shift originates from the electron-donating effect of the methyl group in the DMF molecule—electrons are transferred to Fe through the carbonyl oxygen (C=O). 2+ The d orbitals of Fe make Fe 2+ The increased density of the d-band electron cloud weakens the binding force on electrons, ultimately leading to a decrease in binding energy. Figure 24The XPS spectra of the Fe 2p orbitals of the stripped products show that the coordination mode significantly affects the electronic state of Fe: 2,3,4-TA and 3,4,5-TA bind to Fe through a bidentate coordination mode. This coordination structure enhances the electron delocalization effect, making it easier for the lone pair electrons of the phenolic hydroxyl oxygen atom to transfer to the d orbital of Fe, resulting in a stronger electron-donating effect. Therefore, the Fe 2p binding energy of the corresponding products shifts to a lower energy direction by about 0.2 eV. On the other hand, 2,4,6-TA forms a monodentate coordination with Fe, with a weaker electron-donating effect. Therefore, the Fe 2p binding energy of its products does not shift significantly and is similar to the binding energy of the original pyrite. Figure 25 The images show the ESR spectra of primitive pyrite and Pyrite-DMF. The ESR spectrum of primitive pyrite exhibits a broad peak, which originates from its low-spin state characteristics. This broad paramagnetic signal is due to S vacancies in the crystal and Fe produced by partial oxidation. 3+ Impurities were the main contributors. After DMF pretreatment, the ESR signal of Pyrite-DMF significantly decreased and quenched, presumably because the solvation effect of DMF caused the dissociation of S vacancies and the dissolution of some Fe. 3+ Impurities reduce the number of paramagnetic centers. Figure 26 The ESR spectra of five small molecule acids show that no obvious ESR signal was detected, indicating that the small molecule acids themselves do not have spin resonance centers and do not have unpaired electrons. Figure 27 The ESR spectrum of the stripped product also showed no obvious paramagnetic signal, confirming the absence of unpaired electron paramagnetic centers and the absence of obvious defects in the crystal structure; combined with the Fe in pyrite... 2+ electronic configuration (d 6 The presence of Fe in the product in a low-spin state (without unpaired electrons) further verifies that the stripping process did not damage the crystal integrity of pyrite, and that coordination kept the electronic state of Fe stable.
[0153] Figure 28 The image shows the physical samples of the three strong acid systems (0.1 M acetic acid, 0.1 M nitric acid, and 0.1 M hydrochloric acid) in Comparative Example 1. It can be seen that the upper layer of the system is clear and without suspension, which confirms that strong acids cannot achieve the pyrite stripping process and cannot prepare nano-sized pyrite products.
[0154] Figure 29 The yields of different reaction products in Comparative Example 2 were not significantly different from those in Example 1, confirming that coordination is the key to product regulation, and that the power of the CNC ultrasonic cleaner is sufficient to meet the stripping requirements.
[0155] Figure 30The images show TEM images of the different reaction products in Comparative Example 2. The product exfoliated with the assistance of 4-hydroxybenzoic acid (4-HA) and 2,4,6-trihydroxybenzoic acid (2,4,6-TA) is a nanoplatelet with a size of approximately 60 nm, while the product exfoliated with the assistance of 2,3,4-trihydroxybenzoic acid (2,3,4-TA) and 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA) is an ultra-small nanosheet with a size of approximately 5 nm. Their morphology and size are consistent with the product of Example 1, further confirming that coordination is key to product regulation, and that the power of the CNC ultrasonic cleaner is sufficient to meet the exfoliation requirements.
[0156] In summary, through multi-dimensional characterization, this invention demonstrates that pyrite, as a representative natural mineral drug, can effectively swell and loosen its crystal structure and expose active crystal faces through DMF pretreatment. The use of small-molecule acids containing phenolic hydroxyl groups as excipients allows for the controllability of their molecular structure (number of phenolic hydroxyl groups, substitution positions) with Fe coordination modes (monodentate / bident), and synergistic enhancement of the exfoliation effect through electron transfer. The resulting exfoliated product exhibits a complete crystal structure without significant defects, with Fe existing stably in a low-spin state. Furthermore, its morphology (nanoplates / ultra-small nanosheets) and yield can be precisely controlled, while retaining the intrinsic optical and electronic properties of pyrite. This fully verifies the feasibility and superiority of small-molecule acid-assisted liquid-phase ultrasonic exfoliation technology in the refined processing of natural mineral drugs.
Claims
1. A method for small molecule acid-assisted liquid-phase ultrasonic exfoliation of natural mineral drugs, characterized in that, Includes the following steps: (1) Pretreatment of natural mineral drugs: Weigh the original natural mineral drug powder, disperse it in an organic solvent, and perform static soaking treatment. After soaking, dry the natural mineral drug solid for later use. (2) Liquid phase ultrasonic exfoliation: The natural mineral drug and small molecule acid after the pretreatment in step (1) are added to a mixed solvent system of water and organic solvent in sequence. After the mixture is fully mixed and in contact, liquid phase ultrasonic exfoliation is performed. After the treatment is completed, the system is taken out and naturally cooled to room temperature. (3) Product purification: Take the upper suspension of the mixed system after cooling in step (2), centrifuge and collect the bottom precipitate; after washing, collect the precipitate and dry it to obtain a high-purity exfoliated natural mineral drug product.
2. The method according to claim 1, characterized in that, The natural mineral medicines include layered mineral medicines and non-layered mineral medicines; wherein, the layered mineral medicines include talc, montmorillonite, vermiculite, gold-like stone, and blue-like stone; the non-layered mineral medicines include gypsum, realgar, orpiment, cinnabar, mirabilite, native copper, amethyst, ochre, red ochre, halloysite, stamenite, actinolite, and calcite.
3. The method according to claim 1, characterized in that, The small molecule acid is an organic acid containing a phenolic hydroxyl group, selected from one or more of 2,3,4-trihydroxybenzoic acid (2,3,4-TA), 2,4,6-trihydroxybenzoic acid (2,4,6-TA), 3,4,5-trihydroxybenzoic acid (gallic acid, 3,4,5-TA), 4-hydroxybenzoic acid (4-HA), tannic acid (TA), caffeic acid, ferulic acid, salicylic acid, p-hydroxycinnamic acid, vanillic acid, syringic acid, and protocatechuic acid.
4. The method according to claim 1, characterized in that, The organic solvent mentioned in step (1) is anhydrous N,N-dimethylformamide (DMF), and the static soaking treatment time is 5-10 days. After soaking, the upper DMF clear liquid is removed, and the remaining pyrite solid is transferred to a vacuum drying oven to dry for later use.
5. The method according to claim 1, characterized in that, In step (2), the pretreated natural mineral drug and small molecule acid from step (1) are preferably added to a mixed solvent system of water and organic solvent in a molar ratio of 1:1 to 1:
5.
6. The method according to claim 1, characterized in that, In step (2), the mixed solvent system of water and organic solvent is a mixed solvent system of water and DMF, wherein the volume ratio of water to DMF is 10:1-5:
1. The ultrasonic power of the liquid phase ultrasonic stripping treatment in step (2) is 80~300 W, the ultrasonic temperature is 40~80℃, and the time is 1-3h.
7. The method according to claim 1, characterized in that, In step (3), take the upper suspension of the mixed system after cooling in step (2) and remove the natural mineral raw materials that are not completely stripped; centrifuge the collected supernatant at high speed and collect the bottom precipitate; add ultrapure water to the precipitate to redisperse it, repeat the above centrifugation and washing operation 3-4 times, and finally collect the precipitate and dry it under vacuum to obtain high-purity stripped pyrite product.
8. The method according to claim 1, characterized in that, The drying described in steps (1) and (3) is vacuum drying, with the following conditions: drying temperature 30-80℃, drying time 6-48 h, and drying until the product reaches constant weight.
9. A natural mineral medicine prepared by the method of claim 1.
10. The natural mineral medicine according to claim 9, characterized in that, The natural mineral drug product is a 5nm ultra-small nanosheet or a 60nm nanoplate.
